Switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer, revealed results of a clinical trial.

‘Switch maintenance immunotherapy, significantly slows the worsening of a type of bladder cancer called urothelial cancer.’

"This trial, along with another recent study testing a similar approach, bolster the use of switch maintenance treatment, which will likely become a standard of care for metastatic urothelial cancer, a disease characterized by a paucity of advances in decades," said lead author Matthew Galsky, MD, Co-Director of the Center of Excellence for Bladder Cancer at Mount Sinai.





Source-Eurekalert